Page 2 - Astrazeneca

Next pandemic could be more lethal than Covid: AstraZeneca vaccine maker

Future pandemics could be even more lethal than Covid so the lessons learned from the pandemic must not be squandered, one of the creators of the Oxford-AstraZeneca vaccine said.

AstraZeneca blocks Advent's $7.6-bn buyout of Swedish Orphan Biovitrum

The UK drugmaker's opposition meant the offer fell short of the 90 per cent threshold needed for approval

Booster dose of six Covid vaccines safe, increases immunity: Lancet study

Six different COVID-19 boosters are safe and elicit strong immune response in people who have previously received a two-dose course of AstraZeneca or Pfizer vaccines.

Delta variant may have increased ability to evade vaccine immunity: Study

Vaccines are effective in decreasing hospitalization and deaths from Covid-19 infection but the emergence of viral variants of concern may diminish their efficacy, according to a recent study.

AstraZeneca examining impact of new Covid-19 variant on vaccine

The company has also developed an antibody cocktail which can be used both to prevent and to treat Covid-19

SII resumes exports to COVAX, produces 1.25 bn Covishield doses this year

The first batches of Covishield left the SII manufacturing facility in Pune earlier today, for distribution to low- and middle-income countries

AstraZeneca chief credits Oxford vaccine with UK's Covid-19 fight

Soriot was speaking as his company unveiled a major state-of-the-art research and development facility in Cambridge

Covid-19: AstraZeneca opens research centre as UK builds science hub

Prince Charles will be on hand Tuesday when pharmaceutical company AstraZeneca opens a 1 billion-pound research centre near the University of Cambridge

AstraZeneca Covid drug cocktail gives 83% protection over 6 months: Study

The treatment is given in one go, as two sequential shots in the arm

AstraZeneca set for 'modest' profit from Covid-19 vaccine

The Oxford/AstraZeneca vaccine has until now been sold on a not-for-profit basis

AstraZeneca to book modest profit from coronavirus vaccine

British-Swedish pharmaceutical company AstraZeneca said Friday that it will start to book a modest profit from its coronavirus vaccine as it moves away from the nonprofit model

AstraZeneca Pharma India Q2 net profit declines 55% to Rs 12 crore

The drug firm on Tuesday reported a 54.65 per cent decline in its net profit

Pfizer, Astra shots generate more antibodies than natural infection: Study

People who receive the Pfizer or AstraZeneca COVID-19 vaccine have antibody levels significantly higher than those infected with the SARS-CoV-2 virus, according to a study

AstraZeneca pulls request for Swiss approval of Covid-19 shot

AstraZeneca said Thursday that it is withdrawing its application for approval of its COVID-19 vaccine in Switzerland because the country's medical regulator wanted to restrict its use to people over age 50. Switzerland has cleared the BioNTech-Pfizer, Moderna and Johnson & Johnson vaccines for use. However, national medical regulator Swissmedic hadn't yet granted marketing authorization for the AstraZeneca vaccine. The British-Swedish pharmaceutical company said that, since it started rolling submissions for authorization in Switzerland in October 2020, it has been in close communication with the regulator and has continuously provided the requested study results and other pertinent information and documents. AstraZeneca said it has now decided not to pursue the marketing authorization for its COVID-19 vaccine in Switzerland. This decision is based on Swissmedic's requirement to restrict the indication to people 50 years and above. Swissmedic acknowledged AstraZeneca's decision in

UK to donate 20 mn shots of Astra Covid vaccine to developing countries

Johnson made the announcement as he arrived in Rome for a summit of Group of 20 leaders

Astra's Covid-19 vaccine found safe for pregnancy, fertility in study

The rate of miscarriage was roughly the same between the vaccine and placebo groups

WHO chief, Mandaviya talk Covaxin, resuming Covishield supply to COVAX

WHO chief Tedros Adhanom Ghebreyesus discussed the issue of the emergency use listing of Bharat Biotech's COVID-19 vaccine Covaxin and resumption of supplies of the Serum Institute of India-manufactured AstraZeneca vaccine to the COVAX facility among other topics during a telephonic conversation with Health Minister Mansukh Mandaviya. Had a call with @mansukhmandviya, India's Health Minister, to discuss #India's ongoing #COVID19 vaccination programme; the need for a global pandemic agreement; digital health; & traditional medicine. We welcome India's support to strengthen WHO, incl. via flexible, sustainable financing, Ghebreyesus tweeted on Tuesday. The WHO Director-General said that he also discussed with Mandaviya vaccine equity issues: the resumption of SII/AstraZeneca vaccine supplies to #COVAX; the Covaxin Emergency Use Listing process; and technology and license sharing through C-TAP. COVID-19 Technology Access Pool (C-TAP) was launched in May last year for facilitating ...

AstraZeneca sets up clinical data and insights division in India

Drug firm AstraZeneca on Wednesday said it has launched a clinical data and insights division in India for data-related management of its clinical trials. The Bengaluru-based clinical data and insights (CDI) division is a critical advancement to support a growing global portfolio and build on internal data expertise, the drug firm said in a statement. The CDI division works across therapy areas and portfolios, supporting early and late-stage clinical programmes from Phase 1 to Phase 3, with an integrated end-to-end approach for clinical data, analytics, insights and risk management, it added. Currently, a 30-member team, the division is expected to grow to over 100 members by 2022, the drug firm said. "India has seen a constant uptick in investment in areas such as business services, engineering, digital, IT, R&D and product development from global Fortune-500 companies. AstraZeneca in India is no different since its inception, AstraZeneca India has supported the global ...

A step from Covid-19 pills as Merck & Co seeks FDA approval

An application was submitted with the Food and Drug Administration for molnupiravir to treat mild-to-moderate Covid-19 in adults at risk of developing a severe illness that may require hospitalization

AstraZeneca antibody drug effective at treating mild Covid-19 in trial

The cocktail halved the risk of developing severe illness or death compared with a placebo in participants who had been symptomatic for a week or less and weren't hospitalized, Astra said.